Global Cancer Immunotherapy Market 2022 by Company, Regions, Type and Application, Forecast to 2028
The Cancer Immunotherapy market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Cancer Immunotherapy market size is estimated to be worth US$ 78150 million in 2021 and is forecast to a readjusted size of USD 131790 million by 2028 with a CAGR of 7.8% during review period. Lung Cancer accounting for % of the Cancer Immunotherapy global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Monoclonal Antibodies segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Cancer Immunotherapy include Amgen, AstraZeneca, Roche, Bayer, and Bristol-Myers Squibb, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Cancer Immunotherapy market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Chapter 1, to describe Cancer Immunotherapy product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Cancer Immunotherapy, with revenue, gross margin and global market share of Cancer Immunotherapy from 2019 to 2022.
Chapter 3, the Cancer Immunotherapy competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Cancer Immunotherapy market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Cancer Immunotherapy research findings and conclusion, appendix and data source.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Cancer Immunotherapy market size is estimated to be worth US$ 78150 million in 2021 and is forecast to a readjusted size of USD 131790 million by 2028 with a CAGR of 7.8% during review period. Lung Cancer accounting for % of the Cancer Immunotherapy global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Monoclonal Antibodies segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Cancer Immunotherapy include Amgen, AstraZeneca, Roche, Bayer, and Bristol-Myers Squibb, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Cancer Immunotherapy market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
- Monoclonal Antibodies
- Immune Checkpoint Inhibitors
- Immune System Modulators
- Cancer Vaccines
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Melanoma
- Prostate Cancer
- Others
- Amgen
- AstraZeneca
- Roche
- Bayer
- Bristol-Myers Squibb
- Eli Lilly
- Merck
- Novartis
- Pfizer
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
- South America (Brazil, Argentina, Rest of South America)
- Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Chapter 1, to describe Cancer Immunotherapy product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Cancer Immunotherapy, with revenue, gross margin and global market share of Cancer Immunotherapy from 2019 to 2022.
Chapter 3, the Cancer Immunotherapy competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Cancer Immunotherapy market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Cancer Immunotherapy research findings and conclusion, appendix and data source.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of Cancer Immunotherapy
1.2 Classification of Cancer Immunotherapy by Type
1.2.1 Overview: Global Cancer Immunotherapy Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global Cancer Immunotherapy Revenue Market Share by Type in 2021
1.2.3 Monoclonal Antibodies
1.2.4 Immune Checkpoint Inhibitors
1.2.5 Immune System Modulators
1.2.6 Cancer Vaccines
1.3 Global Cancer Immunotherapy Market by Application
1.3.1 Overview: Global Cancer Immunotherapy Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Lung Cancer
1.3.3 Breast Cancer
1.3.4 Colorectal Cancer
1.3.5 Melanoma
1.3.6 Prostate Cancer
1.3.7 Others
1.4 Global Cancer Immunotherapy Market Size & Forecast
1.5 Global Cancer Immunotherapy Market Size and Forecast by Region
1.5.1 Global Cancer Immunotherapy Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Cancer Immunotherapy Market Size by Region, (2017-2022)
1.5.3 North America Cancer Immunotherapy Market Size and Prospect (2017-2028)
1.5.4 Europe Cancer Immunotherapy Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Cancer Immunotherapy Market Size and Prospect (2017-2028)
1.5.6 South America Cancer Immunotherapy Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Cancer Immunotherapy Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Cancer Immunotherapy Market Drivers
1.6.2 Cancer Immunotherapy Market Restraints
1.6.3 Cancer Immunotherapy Trends Analysis
2 COMPANY PROFILES
2.1 Amgen
2.1.1 Amgen Details
2.1.2 Amgen Major Business
2.1.3 Amgen Cancer Immunotherapy Product and Solutions
2.1.4 Amgen Cancer Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 Amgen Recent Developments and Future Plans
2.2 AstraZeneca
2.2.1 AstraZeneca Details
2.2.2 AstraZeneca Major Business
2.2.3 AstraZeneca Cancer Immunotherapy Product and Solutions
2.2.4 AstraZeneca Cancer Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 AstraZeneca Recent Developments and Future Plans
2.3 Roche
2.3.1 Roche Details
2.3.2 Roche Major Business
2.3.3 Roche Cancer Immunotherapy Product and Solutions
2.3.4 Roche Cancer Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 Roche Recent Developments and Future Plans
2.4 Bayer
2.4.1 Bayer Details
2.4.2 Bayer Major Business
2.4.3 Bayer Cancer Immunotherapy Product and Solutions
2.4.4 Bayer Cancer Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 Bayer Recent Developments and Future Plans
2.5 Bristol-Myers Squibb
2.5.1 Bristol-Myers Squibb Details
2.5.2 Bristol-Myers Squibb Major Business
2.5.3 Bristol-Myers Squibb Cancer Immunotherapy Product and Solutions
2.5.4 Bristol-Myers Squibb Cancer Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 Bristol-Myers Squibb Recent Developments and Future Plans
2.6 Eli Lilly
2.6.1 Eli Lilly Details
2.6.2 Eli Lilly Major Business
2.6.3 Eli Lilly Cancer Immunotherapy Product and Solutions
2.6.4 Eli Lilly Cancer Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 Eli Lilly Recent Developments and Future Plans
2.7 Merck
2.7.1 Merck Details
2.7.2 Merck Major Business
2.7.3 Merck Cancer Immunotherapy Product and Solutions
2.7.4 Merck Cancer Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Merck Recent Developments and Future Plans
2.8 Novartis
2.8.1 Novartis Details
2.8.2 Novartis Major Business
2.8.3 Novartis Cancer Immunotherapy Product and Solutions
2.8.4 Novartis Cancer Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 Novartis Recent Developments and Future Plans
2.9 Pfizer
2.9.1 Pfizer Details
2.9.2 Pfizer Major Business
2.9.3 Pfizer Cancer Immunotherapy Product and Solutions
2.9.4 Pfizer Cancer Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 Pfizer Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Cancer Immunotherapy Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Cancer Immunotherapy Players Market Share in 2021
3.2.2 Top 10 Cancer Immunotherapy Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Cancer Immunotherapy Players Head Office, Products and Services Provided
3.4 Cancer Immunotherapy Mergers & Acquisitions
3.5 Cancer Immunotherapy New Entrants and Expansion Plans
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Cancer Immunotherapy Revenue and Market Share by Type (2017-2022)
4.2 Global Cancer Immunotherapy Market Forecast by Type (2023-2028)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Cancer Immunotherapy Revenue Market Share by Application (2017-2022)
5.2 Global Cancer Immunotherapy Market Forecast by Application (2023-2028)
6 NORTH AMERICA BY COUNTRY, BY TYPE, AND BY APPLICATION
6.1 North America Cancer Immunotherapy Revenue by Type (2017-2028)
6.2 North America Cancer Immunotherapy Revenue by Application (2017-2028)
6.3 North America Cancer Immunotherapy Market Size by Country
6.3.1 North America Cancer Immunotherapy Revenue by Country (2017-2028)
6.3.2 United States Cancer Immunotherapy Market Size and Forecast (2017-2028)
6.3.3 Canada Cancer Immunotherapy Market Size and Forecast (2017-2028)
6.3.4 Mexico Cancer Immunotherapy Market Size and Forecast (2017-2028)
7 EUROPE BY COUNTRY, BY TYPE, AND BY APPLICATION
7.1 Europe Cancer Immunotherapy Revenue by Type (2017-2028)
7.2 Europe Cancer Immunotherapy Revenue by Application (2017-2028)
7.3 Europe Cancer Immunotherapy Market Size by Country
7.3.1 Europe Cancer Immunotherapy Revenue by Country (2017-2028)
7.3.2 Germany Cancer Immunotherapy Market Size and Forecast (2017-2028)
7.3.3 France Cancer Immunotherapy Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Cancer Immunotherapy Market Size and Forecast (2017-2028)
7.3.5 Russia Cancer Immunotherapy Market Size and Forecast (2017-2028)
7.3.6 Italy Cancer Immunotherapy Market Size and Forecast (2017-2028)
8 ASIA-PACIFIC BY REGION, BY TYPE, AND BY APPLICATION
8.1 Asia-Pacific Cancer Immunotherapy Revenue by Type (2017-2028)
8.2 Asia-Pacific Cancer Immunotherapy Revenue by Application (2017-2028)
8.3 Asia-Pacific Cancer Immunotherapy Market Size by Region
8.3.1 Asia-Pacific Cancer Immunotherapy Revenue by Region (2017-2028)
8.3.2 China Cancer Immunotherapy Market Size and Forecast (2017-2028)
8.3.3 Japan Cancer Immunotherapy Market Size and Forecast (2017-2028)
8.3.4 South Korea Cancer Immunotherapy Market Size and Forecast (2017-2028)
8.3.5 India Cancer Immunotherapy Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Cancer Immunotherapy Market Size and Forecast (2017-2028)
8.3.7 Australia Cancer Immunotherapy Market Size and Forecast (2017-2028)
9 SOUTH AMERICA BY COUNTRY, BY TYPE, AND BY APPLICATION
9.1 South America Cancer Immunotherapy Revenue by Type (2017-2028)
9.2 South America Cancer Immunotherapy Revenue by Application (2017-2028)
9.3 South America Cancer Immunotherapy Market Size by Country
9.3.1 South America Cancer Immunotherapy Revenue by Country (2017-2028)
9.3.2 Brazil Cancer Immunotherapy Market Size and Forecast (2017-2028)
9.3.3 Argentina Cancer Immunotherapy Market Size and Forecast (2017-2028)
10 MIDDLE EAST & AFRICA BY COUNTRY, BY TYPE, AND BY APPLICATION
10.1 Middle East & Africa Cancer Immunotherapy Revenue by Type (2017-2028)
10.2 Middle East & Africa Cancer Immunotherapy Revenue by Application (2017-2028)
10.3 Middle East & Africa Cancer Immunotherapy Market Size by Country
10.3.1 Middle East & Africa Cancer Immunotherapy Revenue by Country (2017-2028)
10.3.2 Turkey Cancer Immunotherapy Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Cancer Immunotherapy Market Size and Forecast (2017-2028)
10.3.4 UAE Cancer Immunotherapy Market Size and Forecast (2017-2028)
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
1.1 Product Overview and Scope of Cancer Immunotherapy
1.2 Classification of Cancer Immunotherapy by Type
1.2.1 Overview: Global Cancer Immunotherapy Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global Cancer Immunotherapy Revenue Market Share by Type in 2021
1.2.3 Monoclonal Antibodies
1.2.4 Immune Checkpoint Inhibitors
1.2.5 Immune System Modulators
1.2.6 Cancer Vaccines
1.3 Global Cancer Immunotherapy Market by Application
1.3.1 Overview: Global Cancer Immunotherapy Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Lung Cancer
1.3.3 Breast Cancer
1.3.4 Colorectal Cancer
1.3.5 Melanoma
1.3.6 Prostate Cancer
1.3.7 Others
1.4 Global Cancer Immunotherapy Market Size & Forecast
1.5 Global Cancer Immunotherapy Market Size and Forecast by Region
1.5.1 Global Cancer Immunotherapy Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Cancer Immunotherapy Market Size by Region, (2017-2022)
1.5.3 North America Cancer Immunotherapy Market Size and Prospect (2017-2028)
1.5.4 Europe Cancer Immunotherapy Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Cancer Immunotherapy Market Size and Prospect (2017-2028)
1.5.6 South America Cancer Immunotherapy Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Cancer Immunotherapy Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Cancer Immunotherapy Market Drivers
1.6.2 Cancer Immunotherapy Market Restraints
1.6.3 Cancer Immunotherapy Trends Analysis
2 COMPANY PROFILES
2.1 Amgen
2.1.1 Amgen Details
2.1.2 Amgen Major Business
2.1.3 Amgen Cancer Immunotherapy Product and Solutions
2.1.4 Amgen Cancer Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 Amgen Recent Developments and Future Plans
2.2 AstraZeneca
2.2.1 AstraZeneca Details
2.2.2 AstraZeneca Major Business
2.2.3 AstraZeneca Cancer Immunotherapy Product and Solutions
2.2.4 AstraZeneca Cancer Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 AstraZeneca Recent Developments and Future Plans
2.3 Roche
2.3.1 Roche Details
2.3.2 Roche Major Business
2.3.3 Roche Cancer Immunotherapy Product and Solutions
2.3.4 Roche Cancer Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 Roche Recent Developments and Future Plans
2.4 Bayer
2.4.1 Bayer Details
2.4.2 Bayer Major Business
2.4.3 Bayer Cancer Immunotherapy Product and Solutions
2.4.4 Bayer Cancer Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 Bayer Recent Developments and Future Plans
2.5 Bristol-Myers Squibb
2.5.1 Bristol-Myers Squibb Details
2.5.2 Bristol-Myers Squibb Major Business
2.5.3 Bristol-Myers Squibb Cancer Immunotherapy Product and Solutions
2.5.4 Bristol-Myers Squibb Cancer Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 Bristol-Myers Squibb Recent Developments and Future Plans
2.6 Eli Lilly
2.6.1 Eli Lilly Details
2.6.2 Eli Lilly Major Business
2.6.3 Eli Lilly Cancer Immunotherapy Product and Solutions
2.6.4 Eli Lilly Cancer Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 Eli Lilly Recent Developments and Future Plans
2.7 Merck
2.7.1 Merck Details
2.7.2 Merck Major Business
2.7.3 Merck Cancer Immunotherapy Product and Solutions
2.7.4 Merck Cancer Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Merck Recent Developments and Future Plans
2.8 Novartis
2.8.1 Novartis Details
2.8.2 Novartis Major Business
2.8.3 Novartis Cancer Immunotherapy Product and Solutions
2.8.4 Novartis Cancer Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 Novartis Recent Developments and Future Plans
2.9 Pfizer
2.9.1 Pfizer Details
2.9.2 Pfizer Major Business
2.9.3 Pfizer Cancer Immunotherapy Product and Solutions
2.9.4 Pfizer Cancer Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 Pfizer Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Cancer Immunotherapy Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Cancer Immunotherapy Players Market Share in 2021
3.2.2 Top 10 Cancer Immunotherapy Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Cancer Immunotherapy Players Head Office, Products and Services Provided
3.4 Cancer Immunotherapy Mergers & Acquisitions
3.5 Cancer Immunotherapy New Entrants and Expansion Plans
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Cancer Immunotherapy Revenue and Market Share by Type (2017-2022)
4.2 Global Cancer Immunotherapy Market Forecast by Type (2023-2028)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Cancer Immunotherapy Revenue Market Share by Application (2017-2022)
5.2 Global Cancer Immunotherapy Market Forecast by Application (2023-2028)
6 NORTH AMERICA BY COUNTRY, BY TYPE, AND BY APPLICATION
6.1 North America Cancer Immunotherapy Revenue by Type (2017-2028)
6.2 North America Cancer Immunotherapy Revenue by Application (2017-2028)
6.3 North America Cancer Immunotherapy Market Size by Country
6.3.1 North America Cancer Immunotherapy Revenue by Country (2017-2028)
6.3.2 United States Cancer Immunotherapy Market Size and Forecast (2017-2028)
6.3.3 Canada Cancer Immunotherapy Market Size and Forecast (2017-2028)
6.3.4 Mexico Cancer Immunotherapy Market Size and Forecast (2017-2028)
7 EUROPE BY COUNTRY, BY TYPE, AND BY APPLICATION
7.1 Europe Cancer Immunotherapy Revenue by Type (2017-2028)
7.2 Europe Cancer Immunotherapy Revenue by Application (2017-2028)
7.3 Europe Cancer Immunotherapy Market Size by Country
7.3.1 Europe Cancer Immunotherapy Revenue by Country (2017-2028)
7.3.2 Germany Cancer Immunotherapy Market Size and Forecast (2017-2028)
7.3.3 France Cancer Immunotherapy Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Cancer Immunotherapy Market Size and Forecast (2017-2028)
7.3.5 Russia Cancer Immunotherapy Market Size and Forecast (2017-2028)
7.3.6 Italy Cancer Immunotherapy Market Size and Forecast (2017-2028)
8 ASIA-PACIFIC BY REGION, BY TYPE, AND BY APPLICATION
8.1 Asia-Pacific Cancer Immunotherapy Revenue by Type (2017-2028)
8.2 Asia-Pacific Cancer Immunotherapy Revenue by Application (2017-2028)
8.3 Asia-Pacific Cancer Immunotherapy Market Size by Region
8.3.1 Asia-Pacific Cancer Immunotherapy Revenue by Region (2017-2028)
8.3.2 China Cancer Immunotherapy Market Size and Forecast (2017-2028)
8.3.3 Japan Cancer Immunotherapy Market Size and Forecast (2017-2028)
8.3.4 South Korea Cancer Immunotherapy Market Size and Forecast (2017-2028)
8.3.5 India Cancer Immunotherapy Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Cancer Immunotherapy Market Size and Forecast (2017-2028)
8.3.7 Australia Cancer Immunotherapy Market Size and Forecast (2017-2028)
9 SOUTH AMERICA BY COUNTRY, BY TYPE, AND BY APPLICATION
9.1 South America Cancer Immunotherapy Revenue by Type (2017-2028)
9.2 South America Cancer Immunotherapy Revenue by Application (2017-2028)
9.3 South America Cancer Immunotherapy Market Size by Country
9.3.1 South America Cancer Immunotherapy Revenue by Country (2017-2028)
9.3.2 Brazil Cancer Immunotherapy Market Size and Forecast (2017-2028)
9.3.3 Argentina Cancer Immunotherapy Market Size and Forecast (2017-2028)
10 MIDDLE EAST & AFRICA BY COUNTRY, BY TYPE, AND BY APPLICATION
10.1 Middle East & Africa Cancer Immunotherapy Revenue by Type (2017-2028)
10.2 Middle East & Africa Cancer Immunotherapy Revenue by Application (2017-2028)
10.3 Middle East & Africa Cancer Immunotherapy Market Size by Country
10.3.1 Middle East & Africa Cancer Immunotherapy Revenue by Country (2017-2028)
10.3.2 Turkey Cancer Immunotherapy Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Cancer Immunotherapy Market Size and Forecast (2017-2028)
10.3.4 UAE Cancer Immunotherapy Market Size and Forecast (2017-2028)
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
LIST OF TABLES
Table 1. Global Cancer Immunotherapy Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Cancer Immunotherapy Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Cancer Immunotherapy Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Cancer Immunotherapy Revenue (USD Million) by Region (2017-2022)
Table 5. Global Cancer Immunotherapy Revenue Market Share by Region (2023-2028)
Table 6. Amgen Corporate Information, Head Office, and Major Competitors
Table 7. Amgen Major Business
Table 8. Amgen Cancer Immunotherapy Product and Solutions
Table 9. Amgen Cancer Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. AstraZeneca Corporate Information, Head Office, and Major Competitors
Table 11. AstraZeneca Major Business
Table 12. AstraZeneca Cancer Immunotherapy Product and Solutions
Table 13. AstraZeneca Cancer Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. Roche Corporate Information, Head Office, and Major Competitors
Table 15. Roche Major Business
Table 16. Roche Cancer Immunotherapy Product and Solutions
Table 17. Roche Cancer Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. Bayer Corporate Information, Head Office, and Major Competitors
Table 19. Bayer Major Business
Table 20. Bayer Cancer Immunotherapy Product and Solutions
Table 21. Bayer Cancer Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. Bristol-Myers Squibb Corporate Information, Head Office, and Major Competitors
Table 23. Bristol-Myers Squibb Major Business
Table 24. Bristol-Myers Squibb Cancer Immunotherapy Product and Solutions
Table 25. Bristol-Myers Squibb Cancer Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. Eli Lilly Corporate Information, Head Office, and Major Competitors
Table 27. Eli Lilly Major Business
Table 28. Eli Lilly Cancer Immunotherapy Product and Solutions
Table 29. Eli Lilly Cancer Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. Merck Corporate Information, Head Office, and Major Competitors
Table 31. Merck Major Business
Table 32. Merck Cancer Immunotherapy Product and Solutions
Table 33. Merck Cancer Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. Novartis Corporate Information, Head Office, and Major Competitors
Table 35. Novartis Major Business
Table 36. Novartis Cancer Immunotherapy Product and Solutions
Table 37. Novartis Cancer Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. Pfizer Corporate Information, Head Office, and Major Competitors
Table 39. Pfizer Major Business
Table 40. Pfizer Cancer Immunotherapy Product and Solutions
Table 41. Pfizer Cancer Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. Global Cancer Immunotherapy Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 43. Global Cancer Immunotherapy Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 44. Breakdown of Cancer Immunotherapy by Company Type (Tier 1, Tier 2 and Tier 3)
Table 45. Cancer Immunotherapy Players Head Office, Products and Services Provided
Table 46. Cancer Immunotherapy Mergers & Acquisitions in the Past Five Years
Table 47. Cancer Immunotherapy New Entrants and Expansion Plans
Table 48. Global Cancer Immunotherapy Revenue (USD Million) by Type (2017-2022)
Table 49. Global Cancer Immunotherapy Revenue Share by Type (2017-2022)
Table 50. Global Cancer Immunotherapy Revenue Forecast by Type (2023-2028)
Table 51. Global Cancer Immunotherapy Revenue by Application (2017-2022)
Table 52. Global Cancer Immunotherapy Revenue Forecast by Application (2023-2028)
Table 53. North America Cancer Immunotherapy Revenue by Type (2017-2022) & (USD Million)
Table 54. North America Cancer Immunotherapy Revenue by Type (2023-2028) & (USD Million)
Table 55. North America Cancer Immunotherapy Revenue by Application (2017-2022) & (USD Million)
Table 56. North America Cancer Immunotherapy Revenue by Application (2023-2028) & (USD Million)
Table 57. North America Cancer Immunotherapy Revenue by Country (2017-2022) & (USD Million)
Table 58. North America Cancer Immunotherapy Revenue by Country (2023-2028) & (USD Million)
Table 59. Europe Cancer Immunotherapy Revenue by Type (2017-2022) & (USD Million)
Table 60. Europe Cancer Immunotherapy Revenue by Type (2023-2028) & (USD Million)
Table 61. Europe Cancer Immunotherapy Revenue by Application (2017-2022) & (USD Million)
Table 62. Europe Cancer Immunotherapy Revenue by Application (2023-2028) & (USD Million)
Table 63. Europe Cancer Immunotherapy Revenue by Country (2017-2022) & (USD Million)
Table 64. Europe Cancer Immunotherapy Revenue by Country (2023-2028) & (USD Million)
Table 65. Asia-Pacific Cancer Immunotherapy Revenue by Type (2017-2022) & (USD Million)
Table 66. Asia-Pacific Cancer Immunotherapy Revenue by Type (2023-2028) & (USD Million)
Table 67. Asia-Pacific Cancer Immunotherapy Revenue by Application (2017-2022) & (USD Million)
Table 68. Asia-Pacific Cancer Immunotherapy Revenue by Application (2023-2028) & (USD Million)
Table 69. Asia-Pacific Cancer Immunotherapy Revenue by Region (2017-2022) & (USD Million)
Table 70. Asia-Pacific Cancer Immunotherapy Revenue by Region (2023-2028) & (USD Million)
Table 71. South America Cancer Immunotherapy Revenue by Type (2017-2022) & (USD Million)
Table 72. South America Cancer Immunotherapy Revenue by Type (2023-2028) & (USD Million)
Table 73. South America Cancer Immunotherapy Revenue by Application (2017-2022) & (USD Million)
Table 74. South America Cancer Immunotherapy Revenue by Application (2023-2028) & (USD Million)
Table 75. South America Cancer Immunotherapy Revenue by Country (2017-2022) & (USD Million)
Table 76. South America Cancer Immunotherapy Revenue by Country (2023-2028) & (USD Million)
Table 77. Middle East & Africa Cancer Immunotherapy Revenue by Type (2017-2022) & (USD Million)
Table 78. Middle East & Africa Cancer Immunotherapy Revenue by Type (2023-2028) & (USD Million)
Table 79. Middle East & Africa Cancer Immunotherapy Revenue by Application (2017-2022) & (USD Million)
Table 80. Middle East & Africa Cancer Immunotherapy Revenue by Application (2023-2028) & (USD Million)
Table 81. Middle East & Africa Cancer Immunotherapy Revenue by Country (2017-2022) & (USD Million)
Table 82. Middle East & Africa Cancer Immunotherapy Revenue by Country (2023-2028) & (USD Million)
Table 1. Global Cancer Immunotherapy Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Cancer Immunotherapy Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Cancer Immunotherapy Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Cancer Immunotherapy Revenue (USD Million) by Region (2017-2022)
Table 5. Global Cancer Immunotherapy Revenue Market Share by Region (2023-2028)
Table 6. Amgen Corporate Information, Head Office, and Major Competitors
Table 7. Amgen Major Business
Table 8. Amgen Cancer Immunotherapy Product and Solutions
Table 9. Amgen Cancer Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. AstraZeneca Corporate Information, Head Office, and Major Competitors
Table 11. AstraZeneca Major Business
Table 12. AstraZeneca Cancer Immunotherapy Product and Solutions
Table 13. AstraZeneca Cancer Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. Roche Corporate Information, Head Office, and Major Competitors
Table 15. Roche Major Business
Table 16. Roche Cancer Immunotherapy Product and Solutions
Table 17. Roche Cancer Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. Bayer Corporate Information, Head Office, and Major Competitors
Table 19. Bayer Major Business
Table 20. Bayer Cancer Immunotherapy Product and Solutions
Table 21. Bayer Cancer Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. Bristol-Myers Squibb Corporate Information, Head Office, and Major Competitors
Table 23. Bristol-Myers Squibb Major Business
Table 24. Bristol-Myers Squibb Cancer Immunotherapy Product and Solutions
Table 25. Bristol-Myers Squibb Cancer Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. Eli Lilly Corporate Information, Head Office, and Major Competitors
Table 27. Eli Lilly Major Business
Table 28. Eli Lilly Cancer Immunotherapy Product and Solutions
Table 29. Eli Lilly Cancer Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. Merck Corporate Information, Head Office, and Major Competitors
Table 31. Merck Major Business
Table 32. Merck Cancer Immunotherapy Product and Solutions
Table 33. Merck Cancer Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. Novartis Corporate Information, Head Office, and Major Competitors
Table 35. Novartis Major Business
Table 36. Novartis Cancer Immunotherapy Product and Solutions
Table 37. Novartis Cancer Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. Pfizer Corporate Information, Head Office, and Major Competitors
Table 39. Pfizer Major Business
Table 40. Pfizer Cancer Immunotherapy Product and Solutions
Table 41. Pfizer Cancer Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. Global Cancer Immunotherapy Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 43. Global Cancer Immunotherapy Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 44. Breakdown of Cancer Immunotherapy by Company Type (Tier 1, Tier 2 and Tier 3)
Table 45. Cancer Immunotherapy Players Head Office, Products and Services Provided
Table 46. Cancer Immunotherapy Mergers & Acquisitions in the Past Five Years
Table 47. Cancer Immunotherapy New Entrants and Expansion Plans
Table 48. Global Cancer Immunotherapy Revenue (USD Million) by Type (2017-2022)
Table 49. Global Cancer Immunotherapy Revenue Share by Type (2017-2022)
Table 50. Global Cancer Immunotherapy Revenue Forecast by Type (2023-2028)
Table 51. Global Cancer Immunotherapy Revenue by Application (2017-2022)
Table 52. Global Cancer Immunotherapy Revenue Forecast by Application (2023-2028)
Table 53. North America Cancer Immunotherapy Revenue by Type (2017-2022) & (USD Million)
Table 54. North America Cancer Immunotherapy Revenue by Type (2023-2028) & (USD Million)
Table 55. North America Cancer Immunotherapy Revenue by Application (2017-2022) & (USD Million)
Table 56. North America Cancer Immunotherapy Revenue by Application (2023-2028) & (USD Million)
Table 57. North America Cancer Immunotherapy Revenue by Country (2017-2022) & (USD Million)
Table 58. North America Cancer Immunotherapy Revenue by Country (2023-2028) & (USD Million)
Table 59. Europe Cancer Immunotherapy Revenue by Type (2017-2022) & (USD Million)
Table 60. Europe Cancer Immunotherapy Revenue by Type (2023-2028) & (USD Million)
Table 61. Europe Cancer Immunotherapy Revenue by Application (2017-2022) & (USD Million)
Table 62. Europe Cancer Immunotherapy Revenue by Application (2023-2028) & (USD Million)
Table 63. Europe Cancer Immunotherapy Revenue by Country (2017-2022) & (USD Million)
Table 64. Europe Cancer Immunotherapy Revenue by Country (2023-2028) & (USD Million)
Table 65. Asia-Pacific Cancer Immunotherapy Revenue by Type (2017-2022) & (USD Million)
Table 66. Asia-Pacific Cancer Immunotherapy Revenue by Type (2023-2028) & (USD Million)
Table 67. Asia-Pacific Cancer Immunotherapy Revenue by Application (2017-2022) & (USD Million)
Table 68. Asia-Pacific Cancer Immunotherapy Revenue by Application (2023-2028) & (USD Million)
Table 69. Asia-Pacific Cancer Immunotherapy Revenue by Region (2017-2022) & (USD Million)
Table 70. Asia-Pacific Cancer Immunotherapy Revenue by Region (2023-2028) & (USD Million)
Table 71. South America Cancer Immunotherapy Revenue by Type (2017-2022) & (USD Million)
Table 72. South America Cancer Immunotherapy Revenue by Type (2023-2028) & (USD Million)
Table 73. South America Cancer Immunotherapy Revenue by Application (2017-2022) & (USD Million)
Table 74. South America Cancer Immunotherapy Revenue by Application (2023-2028) & (USD Million)
Table 75. South America Cancer Immunotherapy Revenue by Country (2017-2022) & (USD Million)
Table 76. South America Cancer Immunotherapy Revenue by Country (2023-2028) & (USD Million)
Table 77. Middle East & Africa Cancer Immunotherapy Revenue by Type (2017-2022) & (USD Million)
Table 78. Middle East & Africa Cancer Immunotherapy Revenue by Type (2023-2028) & (USD Million)
Table 79. Middle East & Africa Cancer Immunotherapy Revenue by Application (2017-2022) & (USD Million)
Table 80. Middle East & Africa Cancer Immunotherapy Revenue by Application (2023-2028) & (USD Million)
Table 81. Middle East & Africa Cancer Immunotherapy Revenue by Country (2017-2022) & (USD Million)
Table 82. Middle East & Africa Cancer Immunotherapy Revenue by Country (2023-2028) & (USD Million)
LIST OF FIGURES
Figure 1. Cancer Immunotherapy Picture
Figure 2. Global Cancer Immunotherapy Revenue Market Share by Type in 2021
Figure 3. Monoclonal Antibodies
Figure 4. Immune Checkpoint Inhibitors
Figure 5. Immune System Modulators
Figure 6. Cancer Vaccines
Figure 7. Cancer Immunotherapy Revenue Market Share by Application in 2021
Figure 8. Lung Cancer Picture
Figure 9. Breast Cancer Picture
Figure 10. Colorectal Cancer Picture
Figure 11. Melanoma Picture
Figure 12. Prostate Cancer Picture
Figure 13. Others Picture
Figure 14. Global Cancer Immunotherapy Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 15. Global Cancer Immunotherapy Revenue and Forecast (2017-2028) & (USD Million)
Figure 16. Global Cancer Immunotherapy Revenue Market Share by Region (2017-2028)
Figure 17. Global Cancer Immunotherapy Revenue Market Share by Region in 2021
Figure 18. North America Cancer Immunotherapy Revenue (USD Million) and Growth Rate (2017-2028)
Figure 19. Europe Cancer Immunotherapy Revenue (USD Million) and Growth Rate (2017-2028)
Figure 20. Asia-Pacific Cancer Immunotherapy Revenue (USD Million) and Growth Rate (2017-2028)
Figure 21. South America Cancer Immunotherapy Revenue (USD Million) and Growth Rate (2017-2028)
Figure 22. Middle East and Africa Cancer Immunotherapy Revenue (USD Million) and Growth Rate (2017-2028)
Figure 23. Cancer Immunotherapy Market Drivers
Figure 24. Cancer Immunotherapy Market Restraints
Figure 25. Cancer Immunotherapy Market Trends
Figure 26. Amgen Recent Developments and Future Plans
Figure 27. AstraZeneca Recent Developments and Future Plans
Figure 28. Roche Recent Developments and Future Plans
Figure 29. Bayer Recent Developments and Future Plans
Figure 30. Bristol-Myers Squibb Recent Developments and Future Plans
Figure 31. Eli Lilly Recent Developments and Future Plans
Figure 32. Merck Recent Developments and Future Plans
Figure 33. Novartis Recent Developments and Future Plans
Figure 34. Pfizer Recent Developments and Future Plans
Figure 35. Global Cancer Immunotherapy Revenue Share by Players in 2021
Figure 36. Cancer Immunotherapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 37. Global Top 3 Players Cancer Immunotherapy Revenue Market Share in 2021
Figure 38. Global Top 10 Players Cancer Immunotherapy Revenue Market Share in 2021
Figure 39. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 40. Global Cancer Immunotherapy Revenue Share by Type in 2021
Figure 41. Global Cancer Immunotherapy Market Share Forecast by Type (2023-2028)
Figure 42. Global Cancer Immunotherapy Revenue Share by Application in 2021
Figure 43. Global Cancer Immunotherapy Market Share Forecast by Application (2023-2028)
Figure 44. North America Cancer Immunotherapy Sales Market Share by Type (2017-2028)
Figure 45. North America Cancer Immunotherapy Sales Market Share by Application (2017-2028)
Figure 46. North America Cancer Immunotherapy Revenue Market Share by Country (2017-2028)
Figure 47. United States Cancer Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. Canada Cancer Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. Mexico Cancer Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. Europe Cancer Immunotherapy Sales Market Share by Type (2017-2028)
Figure 51. Europe Cancer Immunotherapy Sales Market Share by Application (2017-2028)
Figure 52. Europe Cancer Immunotherapy Revenue Market Share by Country (2017-2028)
Figure 53. Germany Cancer Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. France Cancer Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. United Kingdom Cancer Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Russia Cancer Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Italy Cancer Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. Asia-Pacific Cancer Immunotherapy Sales Market Share by Type (2017-2028)
Figure 59. Asia-Pacific Cancer Immunotherapy Sales Market Share by Application (2017-2028)
Figure 60. Asia-Pacific Cancer Immunotherapy Revenue Market Share by Region (2017-2028)
Figure 61. China Cancer Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Japan Cancer Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. South Korea Cancer Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. India Cancer Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. Southeast Asia Cancer Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. Australia Cancer Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. South America Cancer Immunotherapy Sales Market Share by Type (2017-2028)
Figure 68. South America Cancer Immunotherapy Sales Market Share by Application (2017-2028)
Figure 69. South America Cancer Immunotherapy Revenue Market Share by Country (2017-2028)
Figure 70. Brazil Cancer Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. Argentina Cancer Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. Middle East and Africa Cancer Immunotherapy Sales Market Share by Type (2017-2028)
Figure 73. Middle East and Africa Cancer Immunotherapy Sales Market Share by Application (2017-2028)
Figure 74. Middle East and Africa Cancer Immunotherapy Revenue Market Share by Country (2017-2028)
Figure 75. Turkey Cancer Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Saudi Arabia Cancer Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. UAE Cancer Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 78. Methodology
Figure 79. Research Process and Data Source
Figure 1. Cancer Immunotherapy Picture
Figure 2. Global Cancer Immunotherapy Revenue Market Share by Type in 2021
Figure 3. Monoclonal Antibodies
Figure 4. Immune Checkpoint Inhibitors
Figure 5. Immune System Modulators
Figure 6. Cancer Vaccines
Figure 7. Cancer Immunotherapy Revenue Market Share by Application in 2021
Figure 8. Lung Cancer Picture
Figure 9. Breast Cancer Picture
Figure 10. Colorectal Cancer Picture
Figure 11. Melanoma Picture
Figure 12. Prostate Cancer Picture
Figure 13. Others Picture
Figure 14. Global Cancer Immunotherapy Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 15. Global Cancer Immunotherapy Revenue and Forecast (2017-2028) & (USD Million)
Figure 16. Global Cancer Immunotherapy Revenue Market Share by Region (2017-2028)
Figure 17. Global Cancer Immunotherapy Revenue Market Share by Region in 2021
Figure 18. North America Cancer Immunotherapy Revenue (USD Million) and Growth Rate (2017-2028)
Figure 19. Europe Cancer Immunotherapy Revenue (USD Million) and Growth Rate (2017-2028)
Figure 20. Asia-Pacific Cancer Immunotherapy Revenue (USD Million) and Growth Rate (2017-2028)
Figure 21. South America Cancer Immunotherapy Revenue (USD Million) and Growth Rate (2017-2028)
Figure 22. Middle East and Africa Cancer Immunotherapy Revenue (USD Million) and Growth Rate (2017-2028)
Figure 23. Cancer Immunotherapy Market Drivers
Figure 24. Cancer Immunotherapy Market Restraints
Figure 25. Cancer Immunotherapy Market Trends
Figure 26. Amgen Recent Developments and Future Plans
Figure 27. AstraZeneca Recent Developments and Future Plans
Figure 28. Roche Recent Developments and Future Plans
Figure 29. Bayer Recent Developments and Future Plans
Figure 30. Bristol-Myers Squibb Recent Developments and Future Plans
Figure 31. Eli Lilly Recent Developments and Future Plans
Figure 32. Merck Recent Developments and Future Plans
Figure 33. Novartis Recent Developments and Future Plans
Figure 34. Pfizer Recent Developments and Future Plans
Figure 35. Global Cancer Immunotherapy Revenue Share by Players in 2021
Figure 36. Cancer Immunotherapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 37. Global Top 3 Players Cancer Immunotherapy Revenue Market Share in 2021
Figure 38. Global Top 10 Players Cancer Immunotherapy Revenue Market Share in 2021
Figure 39. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 40. Global Cancer Immunotherapy Revenue Share by Type in 2021
Figure 41. Global Cancer Immunotherapy Market Share Forecast by Type (2023-2028)
Figure 42. Global Cancer Immunotherapy Revenue Share by Application in 2021
Figure 43. Global Cancer Immunotherapy Market Share Forecast by Application (2023-2028)
Figure 44. North America Cancer Immunotherapy Sales Market Share by Type (2017-2028)
Figure 45. North America Cancer Immunotherapy Sales Market Share by Application (2017-2028)
Figure 46. North America Cancer Immunotherapy Revenue Market Share by Country (2017-2028)
Figure 47. United States Cancer Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. Canada Cancer Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. Mexico Cancer Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. Europe Cancer Immunotherapy Sales Market Share by Type (2017-2028)
Figure 51. Europe Cancer Immunotherapy Sales Market Share by Application (2017-2028)
Figure 52. Europe Cancer Immunotherapy Revenue Market Share by Country (2017-2028)
Figure 53. Germany Cancer Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. France Cancer Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. United Kingdom Cancer Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Russia Cancer Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Italy Cancer Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. Asia-Pacific Cancer Immunotherapy Sales Market Share by Type (2017-2028)
Figure 59. Asia-Pacific Cancer Immunotherapy Sales Market Share by Application (2017-2028)
Figure 60. Asia-Pacific Cancer Immunotherapy Revenue Market Share by Region (2017-2028)
Figure 61. China Cancer Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Japan Cancer Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. South Korea Cancer Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. India Cancer Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. Southeast Asia Cancer Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. Australia Cancer Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. South America Cancer Immunotherapy Sales Market Share by Type (2017-2028)
Figure 68. South America Cancer Immunotherapy Sales Market Share by Application (2017-2028)
Figure 69. South America Cancer Immunotherapy Revenue Market Share by Country (2017-2028)
Figure 70. Brazil Cancer Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. Argentina Cancer Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. Middle East and Africa Cancer Immunotherapy Sales Market Share by Type (2017-2028)
Figure 73. Middle East and Africa Cancer Immunotherapy Sales Market Share by Application (2017-2028)
Figure 74. Middle East and Africa Cancer Immunotherapy Revenue Market Share by Country (2017-2028)
Figure 75. Turkey Cancer Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Saudi Arabia Cancer Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. UAE Cancer Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 78. Methodology
Figure 79. Research Process and Data Source
